Related Experiment Video
Updated: Jun 9, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an
Hua-Jay J Cherng1,2, David DeStephano2, Patrick Gould1,3
1Columbia University Irving Medical Center, New York, NY, USA.
Abstract:
Dose intensity is critical in diffuse large B-cell lymphoma (DLBCL) but can be limited by toxicity risk. The influence of treatment intensity, illness burden, and socioeconomic status (SES) on survival in DLBCL has not been evaluated on a patient-level analysis. We performed a retrospective study of 344 patients with DLBCL from an urban academic cancer center; 55% received lower intensity treatment (average relative dose intensity [ARDI] of cyclophosphamide and doxorubicin <0.9). ARDI, performance status (PS), Charlson comorbidity index (CCI), and double expressor lymphoma (DEL) were associated with progression-free (PFS) and overall survival (OS). Lower ARDI was linked to worse illness burden, treatment intolerance, and higher-risk disease features. Lower ARDI was associated with worse PFS (HR 2.59, p < 0.001) and OS (HR 4.26, p < 0.001) as well as DLBCL progression (sHR 1.86 p = 0.004) and non-relapse mortality (NRM) (sHR 5.45 p = 0.001) in competing risks analysis. Comprehensive multidisciplinary care is needed to reduce the risks associated with undertreatment in DLBCL.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...